Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Treatment with Bitter Melon Juice Blocks Growth of Pancreatic Cancer Cells

By LabMedica International staff writers
Posted on 25 Mar 2013
Juice of the bitter melon (Momordica charantia), which has been used in natural Asian medicine for treatment of diabetes, was found to kill pancreatic cancer cells both in vitro and in vivo without noticeable toxicity to normal tissues.

Investigators at the University of Colorado (Aurora, USA) worked with cultures of the pancreatic cancer cell lines BxPC-3, MiaPaCa-2, AsPC-1, and Capan-2 and with a xenograft model of MiaPaCa-2 tumors growing in nude mice. More...
The cell cultures were treated with bitter melon juice while the mice were fed lyophilized bitter melon juice for a period of six weeks.

Results published in the March 8, 2013, online edition of the journal Carcinogenesis revealed that bitter melon juiced decreased cell viability in all four pancreatic carcinoma cell lines by inducing strong apoptotic death. Oral administration of lyophilized bitter melon juice for six weeks inhibited MiaPaCa-2 tumor xenograft growth by 60% without noticeable toxicity in nude mice.

At the molecular level, bitter melon juice was shown to activate caspases and alter expression of Bcl2 family members and cytochrome-c release into the cytosol. Additionally, it decreased survivin and XIAP (X-linked inhibitor of apoptosis protein) but increased p21, CHOP (DNA-damage-inducible transcript 3), and phosphorylated MAPKs (ERK1/2 and p38) levels. In addition, bitter melon juice activated AMP-activated protein kinase (AMPK), a biomarker for cellular energy status. An AMPK inhibitor (Compound C) reversed bitter melon juice-induced caspase 3 activation, suggesting activated-AMPK involvement in the induced apoptosis.

Immunohistochemical analyses of MiaPaCa-2 xenografts showed that bitter melon juice inhibited proliferation, induced apoptosis, and activated AMPK in vivo.

“Three years ago researchers showed the effect of bitter melon extract on breast cancer cells only in a Petri dish. This study goes much, much farther. We used the juice—people especially in Asian countries are already consuming it in quantity. We show that it affects the glucose metabolism pathway to restrict energy and kill pancreatic cancer cells,” said senior author Dr. Rajesh Agarwal, professor of pharmaceutical sciences at the University of Colorado. “It is a very exciting finding. Many researchers are engineering new drugs to target cancer cells’ ability to supply themselves with energy, and here we have a naturally-occurring compound that may do just that.”

Related Links:
University of Colorado


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.